We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Urinary Biomarkers Predict Weaning From Acute Dialysis Therapy

By LabMedica International staff writers
Posted on 29 Nov 2022
Print article
Image: ELISA kit for liver-type fatty acid–binding protein (L-FABP). The level of L-FABP present in urine reflects the level of renal tubular dysfunction (Photo courtesy of Sekisui Medical Co)
Image: ELISA kit for liver-type fatty acid–binding protein (L-FABP). The level of L-FABP present in urine reflects the level of renal tubular dysfunction (Photo courtesy of Sekisui Medical Co)

Acute kidney injury is associated with a higher risk of chronic kidney disease (CKD), end-stage renal disease, and long-term adverse cardiovascular effects. Critically ill patients with acute kidney injury (AKI) requiring renal replacement therapy (RRT) have a poor prognosis.

Several urinary biomarkers that can predict the development of AKI have been identified, including proximal renal tubular damage markers (e.g., liver-type fatty acid–binding protein [L-FABP], hemojuvelin [HJV], and kidney injury molecule 1 [KIM-1]), distal renal tubular damage markers (e.g., neutrophil gelatinase-associated lipocalin [NGAL] ), and inflammation markers (e.g., C-C motif chemokine ligand 14 [CCL14] and interleukin 18 [IL-18].

Nephrologists at the National Taiwan University Hospital (Taipei, Taiwan) and their colleagues prospectively recorded and analyzed clinical variables at several time points: (1) before starting renal replacement therapy (RRT), (2) at the time of weaning off RRT, and (3) 24 hours after stopping RRT. A total of 140 critically ill patients who received RRT at a multicenter referral hospital from August 2016 to January 2019 were enrolled.

At the time of stopping RRT, urine samples were collected and stored at −80 °C until analysis. The urine concentrations of novel AKI biomarkers were determined using enzyme-linked immunosorbent assay kits: renal L-FABP, (Sekisui Medical Co, Ltd, Tokyo, Japan); KIM-1, NGAL, CCL14 and IL-18, (R&D Systems, Minneapolis, MN, USA), HJV, (Cloud-Clone Corp, Katy, TX, USA).

The investigators reported that the 90-day mortality rate was 13.6% (19/140), and 47.9% (67/140) of the patients were successfully weaned from RRT. Cluster analysis showed that the following biomarkers were correlated with estimated glomerular filtration rate at the time of weaning off RRT: urinary neutrophil gelatinase-associated lipocalin, kidney injury molecule 1, hemojuvelin, C-C motif chemokine ligand 14, interleukin 18, and liver-type fatty acid–binding protein (L-FABP). Among these, urinary L-FABP/creatinine (uL-FABP/Cr) at the time of weaning off RRT showed the best predictive performance for mortality (area under the receiver operating characteristic curve = 0.79).

The authors concluded that nearly half of the critically ill AKI-RRT patients in this study were successfully weaned from acute RRT. They demonstrated that uL-FABP/Cr level at the time of weaning from RRT independently predicted being dialysis free for more than 90 days and all-cause mortality. They also showed that a cutoff value of uL-FABP/Cr (log) level ≤ 2.2 μg/g Cr may be useful for clinical decision-making for AKI-RRT patients who attempt to wean off RRT. uL-FABP/Cr can be combined with SOFA score at the time of weaning off RRT to predict being dialysis free and 90-day mortality. The study was published in the November, 2022 issue of the journal Archives of Pathology & Laboratory Medicine.

Related Links:
National Taiwan University Hospital
Sekisui Medical Co, Ltd
R&D Systems
Cloud-Clone Corp

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more